Pityriasis rubra pilaris and human immunodeficiency virus infection

Recently, the occurrence of pityriasis rubra pilaris (PRP) has been reported in patients with HIV infection. It presents different clinical features, and has a poorer prognosis, than the classical adult type of PRP. We report the occurrence of severe PRP in an HIV-infected patient, and review the previously reported cases of this association. We propose the designation of a new category of PRP (type 6), characterized by the presence of HIV infection, usually without immunosuppression, a poor prognosis and response to treatment, and the development of nodulocystic and lichen spinulosus lesions.     

Pityriasis rubra pilaris. A clinico-pathological study with a special reference to autoradiography and histocompatibility antigens

In a clinical study, 27 of 31 cases of pityriasis rubra pilaris (PRP) had two or more of the following clinical features: erythroderma, well-confined healthy islands inside the inflammatory areas, keratoderma of the palms and soles, or visible follicular hyperkeratosis. Histological features were: perifollicular parakeratosis in 26 cases, hyperkeratosis in 27 cases; the number of granular layers varied greatly from case to case and within one specimen; acanthosis was eczematous in 20 cases and psoriasiform in 8 cases. Erythroderma in PRP in this study was self-healing, lasting 2-6 months with one exception, but PRP must as a whole be considered a mild, chronic disease lasting on average 5.7 years. Complete recovery occurred in only 8 patients and 5 of these had had an erythrodermic onset. Serum vitamin A level and tolerance test were normal. No immunological aberrations could be found. The HLA phenotype frequencies in PRP patients did not differ significantly from those in a Finnish control population. The autoradiographic study of the epidermal cells showed an increase in the cell production in the epidermis.